Fractional exhaled nitric oxide — F ENO — methodology and application in asthma epidemiology in Northern Europe

Show simple item record

dc.contributor Helsingin yliopisto, lääketieteellinen tiedekunta fi
dc.contributor Helsingfors universitet, medicinska fakulteten sv
dc.contributor University of Helsinki, Faculty of Medicine, Unit of Clinical Physiology, Helsinki University Central Hospital en
dc.contributor Kliininen tohtoriohjelma fi
dc.contributor Doktorandprogrammet i klinisk forskning sv
dc.contributor Doctoral Program in Clinical Research en
dc.contributor.author Lassmann-Klee, Paul G.
dc.date.accessioned 2021-10-25T11:23:04Z
dc.date.available 2021-10-20
dc.date.available 2021-10-25T11:23:04Z
dc.date.issued 2021-10-30
dc.identifier.uri URN:ISBN:978-951-51-7634-9
dc.identifier.uri http://hdl.handle.net/10138/335643
dc.description.abstract In Northern Europe, the prevalence of asthma differs between countries, but an objective clinical comparison of bronchial inflammation is missing. Therefore, we aimed to study the fractional exhaled nitric oxide FENO, a biomarker of airway inflammation, in population samples of the general populations of Sweden, Finland and Estonia. We further aimed to analyse methodological and physiological features of FENO acquisition, such as mouthwashes and dependency of expiratory flow. We performed clinical interviews (n = 2658), FENO (n = 1498) and skin prick tests (SPT) in a random population from Sweden (Stockholm and Örebro), Finland (Helsinki), and Estonia (Narva and Saaremaa), during 1997–2003. To analyse the methodology of FENO, we performed two pilot clinical studies. Firstly, we measured FENO with an expiratory flow rate of 50 mL/s in a small random sample (12 asthmatic or healthy) and acquired a baseline, then repeated measurements (for 20 min) after a mouthwash with tap water or carbonated water. Additionally, we obtained FENO from 30 volunteers for multiple expiratory flow rates of 50, 30, 100 and 300 mL/s, after different mouthwash settings. With this dataset, we analysed the influence of mouthwashes in multiple-flow FENO and developed a conversion model, with a further cross-validation in five populations: healthy adults, healthy children, and patients with chronic obstructive pulmonary disease (COPD), asthma and alveolitis. In the pilot studies, the tap water mouthwash reduced FENO for only 2 min. The mouthwash with carbonated water lowered FENO more notably, for 12 min. Compared to the tap water mouthwash, the carbonated water mouthwash reduced FENO at all expiratory flows — 50, 30, 100 and 300 mL/s. The carbonated water mouthwash also lowered the maximum airway NO flux (_JawNO), but not the alveolar NO concentration (CANO) or capacity of the airways for NO diffusion (DawNO). We developed a non-linear model to perform FENO estimations obtained at different flows. The cross-validation resulted in a low deviation between estimated ^FENO (from 100 mL/s to 50 mL/s) and measured FENO (at 50 mL/s) in children (0.27 ppb), the mixed adult population (0.28 ppb), and in healthy adults (0.44 ppb). The deviation was higher in patients with COPD (1.16 ppb), alveolitis (1.47 ppb), and asthma (1.68 ppb). We applied the non-linear model to standardise the FENO values at 50 mL/s in the epidemiological study. In the population study, the median (interquartile range) of FENO (ppb) was 15.5 (9.3) in Sweden, in Finland 15.4 (13.6), and in Estonia 12.5 (9.6). We found the lowest FENO in Estonian centres —Saaremaa 13.1 (9.5) and Narva 11.8 (8.6). Asthma was associated with FENO≥25 ppb, odds ratio (OR) 3.91 (95% confidence interval: 2.29–6.32) and adjusted for skin prick test (SPT), iv Paul G. Lassmann-Klee smoking, sex and study centre. Atopy increased the likelihood of asthma, OR 3.19 (2.02–5.11). Having asthma was more likely in Stockholm OR 5.54 (2.18–14.79), Örebro OR 3.38 (1.59– 8.09), Helsinki OR 2.40 (1.04–6.02), and Narva OR 2.45 (1.05–6.19), compared to Saaremaa. We conclude that a carbonated water mouthwash reduces oral NO contamination for 12 min, and is more pronounced than tap water, with multiple flows, without affecting CANO or DawNO. We established a model for converting FENO between multiple expiratory flows, with further tentative use of predicting extended flow parameters, _JawNO and CANO. We confirmed the higher prevalence of allergic airway inflammation and asthma in Sweden and Finland, compared to Estonia. An increased FENO and atopy were independently associated with a higher risk of asthma. Our epidemiological findings support the west–east disparity of allergic diseases. en
dc.description.abstract fi
dc.format.mimetype application/pdf
dc.language.iso en
dc.publisher Helsingin yliopisto fi
dc.publisher Helsingfors universitet sv
dc.publisher University of Helsinki en
dc.relation.isformatof URN:ISBN:978-951-51-7633-2
dc.relation.isformatof Helsinki: Unigrafia, 2021, Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam Universitatis Helsinkiensis. 2342-3161
dc.relation.ispartof URN:ISSN:2342-317X
dc.rights Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty. fi
dc.rights This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited. en
dc.rights Publikationen är skyddad av upphovsrätten. Den får läsas och skrivas ut för personligt bruk. Användning i kommersiellt syfte är förbjuden. sv
dc.subject clinical physiology, epidemiology
dc.title Fractional exhaled nitric oxide — F ENO — methodology and application in asthma epidemiology in Northern Europe en
dc.type.ontasot Väitöskirja (artikkeli) fi
dc.type.ontasot Doctoral dissertation (article-based) en
dc.type.ontasot Doktorsavhandling (sammanläggning) sv
dc.ths Piirilä, Päivi
dc.ths Sovijärvi, Anssi
dc.opn Altraja, Alan
dc.type.dcmitype Text
dc.type.okm 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet fi
dc.type.okm 3121 Allmänmedicin, inre medicin och annan klinisk medicin sv
dc.type.okm 3121 General medicine, internal medicine and other clinical medicine en

Files in this item

Total number of downloads: Loading...

Files Size Format View
lassmann-klee_paul_dissertation_2021.pdf 21.48Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record